heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-03 and is reviewed periodically as new material appears.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
| Property | Value | Notes |
|---|---|---|
| Appearance | White lyophilized powder | Typical for synthetic peptides |
| Solubility | Freely soluble in water | Also soluble in saline |
| Storage temperature | -20 C or below | Protect from repeated freeze-thaw |
| Analytical method | Reverse-phase HPLC | Confirms purity and identity |
| Common synonym | ACTH(4-10) analog | Reflects structural origin |
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
{\displaystyle {\begin{array}{l}{}\\{\ce {^{6}_{4}Be->[5\ {\ce {zs}}]{^{4}_{2}He}+{2_{1}^{1}H}}}\\{\ce {{^{7}_{4}Be}+e^{-}->[53.22\ {\ce {d}}]{^{7}_{3}Li}}}\\{\ce {^{8}_{4}Be->[81.9\ {\ce {as}}]{2_{2}^{4}He}}}\\{\ce {^{10}_{4}Be->[1.387\ {\ce {Ma}}]{^{10}_{5}B}+e^{-}}}\\{\ce {^{11}_{4}Be->[13.76\ {\ce {s}}]{^{11}_{5}B}+e^{-}}}\\{\ce {^{11}_{4}Be->[13.76\ {\ce {s}}]{^{7}_{3}Li}+{^{4}_{2}He}+e^{-}}}\\{\ce {^{12}_{4}Be->[21.46\ {\ce {ms}}]{^{12}_{5}B}+e^{-}}}\\{\ce {^{12}_{4}Be->[21.46\ {\ce {ms}}]{^{11}_{5}B}+{^{1}_{0}n}+e^{-}}}\\{\ce {^{13}_{4}Be->[1\ {\ce {zs}}]{^{12}_{4}Be}+{^{1}_{0}n}}}\\{\ce {^{14}_{4}Be->[4.53\ {\ce {ms}}]{^{13}_{5}B}+{^{1}_{0}n}+e^{-}}}\\{\ce {^{14}_{4}Be->[4.53\ {\ce {ms}}]{^{14}_{5}B}+e^{-}}}\\{\ce {^{14}_{4}Be->[4.53\ {\ce {ms}}]{^{12}_{5}B}+{2_{0}^{1}n}+e^{-}}}\\{\ce {^{15}_{4}Be->[790\ {\ce {ys}}]{^{14}_{4}Be}+{^{1}_{0}n}}}\\{}{\ce {^{16}_{4}Be->[650\ {\ce {ys}}]{^{14}_{4}Be}+{2_{0}^{1}n}}}\\{}\end{array}}}
Regular insulin, also known as neutral insulin and soluble insulin, is a type of short-acting medical insulin. It is used to treat type 1 diabetes, type 2 diabetes, gestational diabetes, and complications of diabetes such as diabetic ketoacidosis and hyperosmolar hyperglycemic states. It is also used along with glucose to treat high blood potassium levels. Typically it is given by injection under the skin, but may also be used by injection into a vein or muscle. Onset of effect is typically in 30 minutes and it typically lasts for 8 hours. The common side effect is low blood sugar. Other side effects may include pain or skin changes at the sites of injection, low blood potassium, and allergic reactions. Use during pregnancy is relatively safe for the baby. Regular insulin can be made from the pancreas of pigs or cows. Human versions can be made either by modifying pig versions or recombinant technology. Insulin was first used as a medication in Canada by Charles Best and Frederick Banting in 1922. It is on the World Health Organization's List of Essential Medicines. In 2017, it was the 209th most commonly prescribed medication in the United States, with more than 2 million prescriptions. Versions are also available mixed with longer-acting versions of insulin, such as NPH insulin. In 2020, the combination of human insulin with insulin isophane was the 246th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
==== Cone snail and fish insulin ==== Conus geographus produces a distinct form of insulin that is more similar to fish insulin protein sequences than to insulin from more closely related molluscs, suggesting convergent evolution, though with the possibility of horizontal gene transfer.
nj are the stoichiometric coefficients of the reactants in the equilibrium equation, and mj are the coefficients of the products. The value of δGr for these reactions is a function of the chemical potentials of all the species.
Sources: en.wikipedia.org
A standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected. (ICH E6)
===== PI 88788 ===== The vast majority of cultivars in the US have soybean cyst nematode resistance (SCN resistance), but rely on only one breeding line (PI 88788) as their sole source of resistance. (The resistance genes provided by PI 88788, Peking, and PI 90763 were characterized in 1997.) As a result, for example, in 2012 only 18 cultivars out of 807 recommended by the Iowa State University Extension had any ancestry outside of PI 88788. By 2020 the situation was still about the same: Of 849 there were 810 with some ancestry from PI 88788, 35 from Peking, and only 2 from PI 89772. (On the question of exclusively PI 88788 ancestry, that number was not available for 2020.) That was speculated to be in 2012—and was clearly by 2020—producing SCN populations that are virulent on PI 88788.
backbone Also main chain. The primary or most structurally significant portion of a molecule with respect to its other parts, functional groups, moieties, or substituents; or, in the case of a polymer, that linear chain of atoms to which all other chains, long or short or both, may be regarded as being pendant or as side chains. Where two or more chains might equally be considered the backbone, the one which permits the simplest representation of the molecule in chemical formulae and nomenclature is considered the backbone.
Sources: en.wikipedia.org
Films often portray mental illness through exaggerated or negative stereotypes, which can distort public understanding and reinforce stigma, and they have often been negative, inaccurate or violent representations. Often distorted or overrepresented to be more sensational. A side to the misrepresentation of people with mental illness as less able to engage in healthy living and adversity management is the overrepresentation of characters as erratic, violent, and dangerous; horror films are particularly notorious for crude depictions of mental illness as monstrous. Psychologists have advocated for more accurate depictions, when these often reinforce self-stigma, and make mentally ill individuals feel like they can become horrific killers too. The other side is its romantization, where in the effort to craft a compelling tale, film makers will often embellish, simplify, or decontextualize complex mental health conditions, resorting to unrealistic tropes where "willpower" or "love" can "conquer" mental illness. A study published by Scarf, et al. in 2020 looked at a recent example, the popular film Joker (2019), which portrays the lead character as a person with mental illness who becomes extremely violent. The study found that viewing the film "was associated with higher levels of prejudice toward those with mental illness." Additionally, the authors suggest, "Joker may exacerbate self-stigma for those with a mental illness, leading to delays in help seeking." Positive portrayals of mental illness have generally increased since the 20th century.
Protein targeting or protein sorting is the biological mechanism by which proteins are transported to their appropriate destinations within or outside the cell. Proteins can be targeted to the inner space of an organelle, different intracellular membranes, the plasma membrane, or to the exterior of the cell via secretion. Information contained in the protein itself directs this delivery process. Correct sorting is crucial for the cell; errors or dysfunction in sorting have been linked to multiple diseases.
==== United States Champion; departure (1993–1994) ==== At Starrcade '93: 10th Anniversary in December 1993, Austin defeated Dustin Rhodes 2–0 in a two-out-of-three-falls match to win the WCW United States Championship. At Clash of the Champions XXVIII in August 1994, Austin lost the Championship to Ricky Steamboat. He was scheduled to face Steamboat in a rematch at Fall Brawl '94: War Games in September 1994; however, Steamboat was unable to wrestle due to a legitimate back injury and Austin was awarded the championship by forfeit. His second reign with the championship ended just five minutes later when he lost to Steamboat's replacement, Jim Duggan, in a match that lasted 35 seconds. Austin unsuccessful challenged Duggan for the championship at both Halloween Havoc in October 1994 and Clash of the Champions XXIX in November 1994. The influence of Hulk Hogan and the Hulkamania era was beginning to take hold in WCW, with vice president Eric Bischoff saying this was likely the reason Austin lost to Duggan, who had been a popular figure during that period of time. Around this time, Austin pitched a storyline idea to Bischoff in which it would be revealed that Austin was a family member of Hogan. The proposal was quickly turned down on account of Bischoff's belief that Hogan would not work with somebody such as Austin, who was not a proven name. Following Clash of the Champions XXIX, Austin was inactive while rehabilitating a knee injury, returning in February 1995.
However, there is significant charge transfer between the two materials and, in some cases, hybridization between the d-orbitals of the substrate atoms and π orbitals of graphene, which significantly alter the electronic structure compared to that of free-standing graphene. Boehm et al. coined the term "graphene" for the hypothetical single-layer structure in 1986. The term was used again in 1987 to describe single sheets of graphite as a constituent of graphite intercalation compounds, which can be seen as crystalline salts of the intercalant and graphene. It was also used in the descriptions of carbon nanotubes by R. Saito and Mildred and Gene Dresselhaus in 1992, and in the description of polycyclic aromatic hydrocarbons in 2000 by S. Wang and others. Efforts to make thin films of graphite by mechanical exfoliation started in 1990. Initial attempts employed exfoliation techniques similar to the drawing method. Multilayer samples down to 10 nm in thickness were obtained. In 2002, Robert B. Rutherford and Richard L. Dudman filed for a patent in the US on a method to produce graphene by repeatedly peeling off layers from a graphite flake adhered to a substrate, achieving a graphite thickness of 0.00001 inches (0.00025 millimetres). The key to success was the ability to quickly and efficiently identify graphene flakes on the substrate using optical microscopy, which provided a small but visible contrast between the graphene and the substrate. Another U.S. patent was filed in the same year by Bor Z. Jang and Wen C.
Sources: en.wikipedia.org
It is associated with the melanocortin receptor family, particularly subtypes found in the central nervous system. This interaction is separate from the adrenal pathway activated by full-length ACTH.
Peptidases degrade the compound within minutes in circulation. This short half-life is one reason nasal delivery is used, placing the substance close to the olfactory and trigeminal pathways.
No large multicenter trials have been published in English-language journals. The existing human evidence consists mainly of smaller studies conducted in Russia, which limits generalization.
The sequence is Met-Glu-His-Phe-Pro-Gly-Pro, a seven-residue peptide. The first four residues correspond to the ACTH(4-10) fragment, and Pro-Gly-Pro is added at the C-terminus. N-acetylated versions also appear in the literature and differ in mass.